Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.
Storb
R
R
Leisenring
W
W
Anasetti
C
C
Appelbaum
F R
FR
Buckner
C D
CD
Bensinger
W I
WI
Chauncey
T
T
Clift
R A
RA
Deeg
H J
HJ
Doney
K C
KC
Flowers
M E
ME
Hansen
J A
JA
Martin
P J
PJ
Sanders
J E
JE
Sullivan
K M
KM
Witherspoon
R P
RP
D000293:Adolescent; D000328:Adult; D000477:Alkylating Agents / Q000009:adverse effects; D000741:Anemia, Aplastic / Q000401:mortality / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology*; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000477:Alkylating Agents; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide